NCT00722969Unknown2 期
A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Free University Medical Center4 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 48
- 试验地点
- 4
- 主要终点
- Rate of non-progression at 6 weeks
研究概览
简要总结
Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib 400 mg twice a day. The objectives of the study are to assess the efficacy and safety of this combination treatment. Additional exploratory study objectives are correlation of biomarkers and imaging modalities potentially predictive for response and (progression free) survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically/cytologically advanced NSCLC stage IIIB or IV
- •No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal antibody therapy) or prior exposure to agents directed at the HER axis (e.g. EGFR TK inhibitors, Herceptin). Prior surgery and/or localized irradiation is permitted provided that the irradiated lesion is not the only measurable lesion.
- •Age > 18 years.
- •ECOG Performance Status of 0 or 1
- •Life expectancy of at least 12 weeks.
- •Subjects with at least one uni-dimensional(for RECIST) measurable lesion. Lesions must be measured by CT-scan.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin > 9.0 g/dl
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Platelet count > 100,000/μl
- •Total bilirubin < 1.5 times the upper limit of normal
- •ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer)
- •Alkaline phosphatase < 4 x ULN
- •PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with low molecular weight heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.]
- •Serum creatinine < 1.5 x upper limit of normal.
- •Written informed consent.
排除标准
- •Excluded medical conditions:
- •History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy( beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •History of HIV infection or chronic hepatitis B or C.
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Symptomatic metastatic brain or meningeal tumors (unless the patient is > 1 months from definitive radiotherapy and off steroids):
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft.
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •Excluded therapies and medications, previous and concomitant:
- •Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry.
- •Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed). Major surgery within 3 weeks of start of study
- •Autologous bone marrow transplant or stem cell rescue within 4 months of study
- •Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study]
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •Prior exposure to the study drugs.
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •Patients unable to swallow oral medications.
研究组 & 干预措施
A
Experimental
干预措施: sorafenib + erlotinib (Drug)
结局指标
主要结局
Rate of non-progression at 6 weeks
时间窗: 6 weeks
次要结局
- Survival(End of study)
- Best overall response rate(end of study)
- Duration of response(End of study)
- Prediction of early response and effects on tumor vascularisation by PET and perfusion CT scans(Baseline, week 3 and week 6)
- Biomarkers for response (Proteomics, circulating cells, mutational analysis)(Baseline, week 1, week 3 and week 6)
- Toxicity(Week 1, week 3, week 6, week 9, week 12 then every 6 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)Lung CancerNCT01562028ETOP IBCSG Partners Foundation109
进行中（未招募）
不适用
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy - phase II erlotinib-sorafenib in advanced NSCLCAdvanced non small cell lung cancerEUCTR2007-004625-14-NLVU University Medical Centre48
尚未招募
2 期
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapyNon small cell lung cancer10038666NL-OMON31390Vrije Universiteit Medisch Centrum48
招募中
2 期
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung CancerEGFRLocally Advanced Non-Small Cell Lung CancerPemetrexedCarboplatinBevacizumabAntineoplastic AgentsTyrosine Kinase InhibitorNon-Small Cell Lung CancerNCT06755684Peng Zhang60
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40